Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NUTEX InvestmentsBUD:NUTEX -5.22%52 Return-on-Tangible-Asset is 14.08% as of Dec. 2025, which is 2135% above its 10-year median of 0.63. GuruFocus rates BUD:NUTEX with a GF Score™ of 52/100 and a GF Value™ of Ft13.80 (Fairly Valued). The stock has 3 warning signs investors should review. Among 1,007 Drug Manufacturers companies, NUTEX Investments ranks better than 76.66% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. NUTEX Investments's annualizedNet Income for the quarter that ended in Dec. 2025 was Ft757.64 Mil. NUTEX Investments's average total tangible assets for the quarter that ended in Dec. 2025 was Ft5,379.56 Mil. Therefore, NUTEX Investments's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was 14.08%.
The historical rank and industry rank for NUTEX Investments's Return-on-Tangible-Asset or its related term are showing as below:
BUD:NUTEX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -30.07 Med: 0.63 Max: 9.41
Current: 9.41
During the past 13 years, NUTEX Investments's highest Return-on-Tangible-Asset was 9.41%. The lowest was -30.07%. And the median was 0.63%.
BUD:NUTEX's Return-on-Tangible-Asset is ranked better than 76.66% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 3.15
vs BUD:NUTEX: 9.41
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
NUTEX Investments Return-on-Tangible-Asset Related Terms
NUTEX Investments Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for NUTEX Investments's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NUTEX vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NUTEX Investments Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where NUTEX Investments's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 14.08% mean?
NUTEX Investments (BUD:NUTEX) has a Return-on-Tangible-Asset of 14.08% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on NUTEX Investments and its competitors. This is 2135% above median its historical median of 0.63. According to the industry distribution chart, NUTEX Investments ranks #235 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 23.3%.
Is NUTEX Investments' Return-on-Tangible-Asset too high?
NUTEX Investments' current Return-on-Tangible-Asset of 14.08% is 2135% above median its 10-year median of 0.63. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.15. NUTEX Investments' value of 14.08% is 347% above this industry median. Based on the distribution chart, NUTEX Investments ranks #235 out of 1007 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, NUTEX Investments has a GF Score™ of 52/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NUTEX Investments ranks #235 out of 1007 companies for Return-on-Tangible-Asset. This places NUTEX Investments in the top 23% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.15. NUTEX Investments' value of 14.08% is 347% above this benchmark. While the company's 10-year median is 0.63 vs. the industry median of 3.15, NUTEX Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.15, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NUTEX Investments's current Return-on-Tangible-Asset of 14.08% is 347% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on NUTEX Investments and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NUTEX Investments's current Return-on-Tangible-Asset is 14.08%, which is 2135% above median its own 10-year median of 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
Based on GuruFocus' analysis, NUTEX Investments (BUD:NUTEX) is currently considered Fairly Valued. The stock's GF Value™ is Ft13.80, compared to a current price of Ft12.70 — trading 8% below its estimated fair value. The current Return-on-Tangible-Asset is 14.08%, which is 2135% above median its 10-year median of 0.63 and 347% above the Drug Manufacturers industry median of 3.15. NUTEX Investments' overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current Return-on-Tangible-Asset is 14.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NUTEX Investments (BUD:NUTEX) Overvalued in 2026?
Based on GuruFocus' analysis, NUTEX Investments stock appears to be undervalued.
The current stock price of Ft12.70 is trading 8% below its estimated GF Value™ of Ft13.80.
GuruFocus considers NUTEX Investments to be Fairly Valued.
Key valuation signals for BUD:NUTEX:
Return-on-Tangible-Asset: 14.08% (2135% above median its 10-year median of 0.63)
GF Value™: Ft13.80 vs. price of Ft12.70 (8% below fair value)
Industry Position: 347% above the Drug Manufacturers median (#235 of 1007)
No single metric tells the full story. See the BUD:NUTEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
52GF Score
Get the complete analysis for BUD:NUTEX
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NUTEX has been successfully added to your 
